Remdesivir cost effective for severe COVID-19 in China

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085793/
https://www.ncbi.nlm.nih.gov/pubmed/33948076
http://dx.doi.org/10.1007/s40274-021-7666-3
_version_ 1783686417229021184
collection PubMed
description
format Online
Article
Text
id pubmed-8085793
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-80857932021-04-30 Remdesivir cost effective for severe COVID-19 in China PharmacoEcon Outcomes News Clinical Study Springer International Publishing 2021-05-01 2021 /pmc/articles/PMC8085793/ /pubmed/33948076 http://dx.doi.org/10.1007/s40274-021-7666-3 Text en © Springer International Publishing AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Clinical Study
Remdesivir cost effective for severe COVID-19 in China
title Remdesivir cost effective for severe COVID-19 in China
title_full Remdesivir cost effective for severe COVID-19 in China
title_fullStr Remdesivir cost effective for severe COVID-19 in China
title_full_unstemmed Remdesivir cost effective for severe COVID-19 in China
title_short Remdesivir cost effective for severe COVID-19 in China
title_sort remdesivir cost effective for severe covid-19 in china
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085793/
https://www.ncbi.nlm.nih.gov/pubmed/33948076
http://dx.doi.org/10.1007/s40274-021-7666-3

Ejemplares similares